In contrast, a CRC-specific evaluation of patients treated with first-line FOLFIRI plus cetuximab or bevacizumab in the FIRE-3 trial16 suggested that patients with CH, in particular DNMT3A alterations, actually had an improved OS but no differences in PFS in this treatment setting. This evidence concerns the gene DNMT3A and colorectal carcinoma.